Overall Impact of Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Michael Weiner, MD
Professor of Radiology
University of California, San Francisco

Objectives

• Understand the evolving history of biomarkers for Alzheimer’s disease
• Understand how the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has contributed to overall understanding of AD pathophysiology and to design of clinical trials
• How to develop digital screening assessments and blood testing as a gateway to observational research and clinical trials
• Latest advances in blood and CSF testing for various biomarkers of neurodegenerative disease

Disclosures

• Planners: Bruce L. Miller, MD; Howard J. Rosen, MD; Andrew Breithaupt, MD; and Eleanor O’Brien have stated they have no relationships to disclose.
• Speakers: Michael Weiner, MD, has disclosed the following relationships: editorial boards for Alzheimer’s & Dementia and the Journal for Prevention of Alzheimer’s Disease; advisory boards for Acumen Pharmaceutical, Alzheon, Inc., Cerecin, Merck Sharp & Dohme Corp., and NC Registry for Brain Health; the USC ACTC grant which receives funding from Eisai for the AHEAD study; consulting to Boxer Capital, LLC, Cerecin, Inc., Clario, Dementia Society of Japan, Eisai, Guidepoint, Health and Wellness Partners, Indiana University, LCN Consulting, Merck Sharp & Dohme Corp., NC Registry for Brain Health, Prova Education, T3D Therapeutics, University of Southern California (USC), and WebMD; speaker/lecturer for China Association for Alzheimer’s Disease (CAAD) and Taipei Medical University, as well as a speaker/lecturer with academic travel funding provided by: AD/PD Congress, Cleveland Clinic, CTAD Congress, Foundation of Learning; Health Society (Japan), INSPIRE Project; U. Toulouse, Japan Society for Dementia Research, and Korean Dementia Society, Merck Sharp & Dohme Corp., National Center for Geriatrics and Gerontology (NCGG; Japan), University of Southern California (USC). He holds stock options with Alzheon, Inc., Alzeca, ALZPath, Inc., and Anven. He has received support for his research from the following funding sources: National Institutes of Health (NIH)/NINDS/National Institute on Aging (NIA), Department of Defense (DOD), California Department of Public Health (CDPH), University of Michigan, Siemens, Biogen, Hillblom Foundation, Alzheimer’s Association, Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI-BHR), The Stroke Foundation, and the Veterans Administration.

Accreditation: The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation: UCSF designates this live activity for a maximum of 22 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit is inclusive of all Memory and Aging Center Grand Rounds sessions offered from January 1, 2023, through December 31, 2023. (1 credit per each 1-hour grand rounds session throughout the year).

Questions? Email Andrew Breithaupt, MD, at Andrew.Breithaupt@ucsf.edu.

Attendees must register for this event. Grand Rounds presentations are for educational purposes and intended for a professional audience with a terminal degree. This activity is not commercially supported.